Bayer Hits Par With Patent Suit Over Staxyn Generic
Bayer Pharma AG on Tuesday hit generic-drug maker Par Pharmaceutical Inc. with a suit in Delaware federal court, accusing its rival of infringing on two patents with a planned generic version...To view the full article, register now.
Already a subscriber? Click here to view full article